These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10520974)

  • 1. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
    Nurnberg HG; Thompson PM; Hensley PL
    J Clin Psychiatry; 1999 Sep; 60(9):574-9. PubMed ID: 10520974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.
    Ball SG; Kuhn A; Wall D; Shekhar A; Goddard AW
    J Clin Psychiatry; 2005 Jan; 66(1):94-9. PubMed ID: 15669894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
    Crown WH; Treglia M; Meneades L; White A
    Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
    Nurnberg HG; Hensley PL; Thompson PM; Paine SS
    Psychiatr Serv; 1999 Oct; 50(10):1351-3. PubMed ID: 10506306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
    Polsky D; Onesirosan P; Bauer MS; Glick HA
    J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
    Lam D; Gorman DA; Patten S; Pringsheim T
    Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia.
    McManus P; Mant A; Mitchell P; Dudley J
    Aust N Z J Psychiatry; 2004 Jun; 38(6):450-4. PubMed ID: 15209838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
    Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
    J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic appraisal of citalopram in the management of single-episode depression.
    Sclar DA; Skaer TL; Robison LM; Galin RS
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
    Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
    J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
    Zhang Y; Becker T; Ma Y; Koesters M
    BMC Psychiatry; 2014 Aug; 14():245. PubMed ID: 25159460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.